Skip to content

Cash ratio at other companies

IAR
Integra LifeSciencesIART
0.7×+0.4×
Organogenesis Holdings Inc. logo
Organogenesis Holdings Inc.ORGO
1.2×-0.5×
Artivion logo
ArtivionAORT
0.6×-0.1×
Solventum logo
SolventumSOLV
0.2×0.0×
Vericel logo
VericelVCEL
2.3×+0.3×
Enovis logo
EnovisENOV
0.1×0.0×

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Calculated from MiMedx Group’s reported figures.

Based on the most recent quarter.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's cash ratio?
MiMedx Group (MDXG) reported cash ratio of 3.6× in Q1 2026.
How has MiMedx Group's cash ratio changed year-over-year?
MiMedx Group's cash ratio increased by 43.6% year-over-year, from 2.5× to 3.6×.
What is the long-term trend for MiMedx Group's cash ratio?
Over 5 years (2020 to 2025), MiMedx Group's cash ratio has grown at a 9.8% compound annual growth rate (CAGR), from 1.6× to 2.6×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.